FDA approves Omvoh for moderately to severely active Crohn's disease
The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...
Hosted on MSN2d
Eli Lilly: 4 Reasons Investors Shouldn't Miss This Opportunity
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Pharmaceutical Technology on MSN1d
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
Eli Lilly has received approval from the US FDA for Omvoh to treat moderately to severely active Crohn's disease in the adult ...
Reuters15d
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...
S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens
The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's ...
Prediction: These 3 Healthcare Stocks Will Soar in 2025
This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...
Yahoo Finance22d
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
It seems like just yesterday that vaccines used to combat the COVID-19 pandemic were all anyone in the medical world could talk about. Companies such as Pfizer, Moderna, and Johnson & Johnson ...
Investor's Business Daily on MSN1d
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.